Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05972993 · ClinicalTrials.gov registry record · Phase 1
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
A Phase 1 study of COVID-19, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 114
- Enrollment target
- 4
- Study locations
NCT05972993: Completed Phase 1 study of COVID-19, sponsored by GlaxoSmithKline.
NCT05972993 is a Phase 1 study of COVID-19 that has completed, run by GlaxoSmithKline. The registered enrollment target is 114 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05972993, a Phase 1 study of COVID-19, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 114 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults previously vaccinated with SARS-CoV-2 mRNA vaccines.
Primary Outcome
The solicited administration site events are pain, redness, swelling and lymphadenopathy (axillary swelling/ tenderness on the same side of the body as the site of injection). Any = occurrence of the event regardless of intensity grade.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL mRNA-CR-04 vaccine 10μg
- BIOLOGICAL mRNA-CR-04 vaccine 30μg
- BIOLOGICAL mRNA-CR-04 vaccine 100μg
- BIOLOGICAL mRNA-CR-04 vaccine 3μg
Study Locations (4)
California
- GSK Investigational Site - San Diego
Florida
- GSK Investigational Site - Melbourne
Illinois
- GSK Investigational Site - Peoria
Texas
- GSK Investigational Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2023-08-07 |
| Est. Completion | 2024-10-14 |
| Phase | Phase 1 |
What the finished NCT05972993 record still lists
NCT05972993 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT05972993 reports a single indexed study location in California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05972993 about?
NCT05972993 is a clinical study titled "A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults". The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults previously vaccinated with SARS-CoV-2 mRNA vaccines.
What is the current status of trial NCT05972993?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 114 participants. The study started on 2023-08-07. Estimated completion is 2024-10-14.
What conditions does trial NCT05972993 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT05972993?
The interventions under investigation include: Placebo (DRUG), mRNA-CR-04 vaccine 10μg (BIOLOGICAL), mRNA-CR-04 vaccine 30μg (BIOLOGICAL), mRNA-CR-04 vaccine 100μg (BIOLOGICAL), mRNA-CR-04 vaccine 3μg (BIOLOGICAL).
Who is sponsoring clinical trial NCT05972993?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05972993 being conducted?
This trial has 4 study locations across California, Florida, Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05972993's enrollment target sits among peer trials
114 190th of 298 higher than 109 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
RECRUITING · Phase 1
-
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
RECRUITING · Phase 1
-
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
RECRUITING · Phase 1
-
A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers
ACTIVE NOT RECRUITING · Phase 1
-
Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI